Mainz Biomed BV (MYNZ)

[Monksdream]

MYNZ new 52 week low

[Monksdream]

MYNZ under $2

[Monksdream]

MYNZ under $2

[Monksdream]

MYNZ new 52 week low

[D60510]

Looking for strong upside for this stock in the March-June 2024 timeliness. Should be aver 3.00 imo

[gail]

here comes the eod run up after the little dip there.

[gail]

weeeeeee!

[gail]

grabbed some this morning at 3.89.

[Triple nickle]

Still stable

[BooDog]

That cat bounced. Poped back over $4.

[BooDog]

Watching for the dead cat bounce.

[Mrogers23]

$MYNZ Mainz Biomed Provides Full Year 2022 Financial Results

ColoAlert Revenue Increases 130% Year over Year

Year End Cash Balance of $17.1 Million

BERKELEY, Calif. and MAINZ, Germany, April 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the fiscal year ended December 31, 2022.

[Mrogers23]

This Could Send Mainz Biomed (MYNZ) Soaring Past Wainwright’s $25 Target https://smallcapexclusive.com/this-could-send-mainz-biomed-mynz-soaring-past-wainwrights-25-target/

[Mrogers23]

$MYNZ Analysts Model Over 74% Upside For Mainz Biomed Stock Ahead Of Key 1/H 2023 Updates https://www.benzinga.com/pressreleases/23/03/ab31469781/analysts-model-over-74-upside-for-mainz-biomed-stock-ahead-of-key-1h-2023-updates-mynz

[BEIJING BILL]

But some... heering fda approval rumbles here.

[Mrogers23]

$MYNZ Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany

BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber & Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany.

Read for release: https://finance.yahoo.com/news/mainz-biomed-announces-partnership-labor-070100006.html

[Mrogers23]

$MYNZ Mainz Biomed Nears Multiple Data Set Releases Expected To Fuel 2023 Growth

Mainz Biomed's share price weakness presents an opportunity to trade ahead of potential near-term catalysts. Shares dropped on Monday, possibly in sympathy with the Silicon Valley Bankfiasco. However, while MYNZ does list a Berkeley, California connection on its byline, this company is primarily based in Germany. Thus, financial exposure, if any, is more of a distraction than an MYNZ-specific event. Moreover, its significance is outweighed by the planned data releases expected over the next 90 days.

Read full release:

[Mrogers23]

$MYNZ Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection

https://finance.yahoo.com/news/mainz-biomed-launches-number-educational-080100640.html

[Mrogers23]

Mainz Biomed has laid the groundwork in 2022 for what could be a transformative 2023. That means from a market cap perspective, its roughly $98 million level could be undervaluing much of the progress made last year. In fact, current valuations could be considered accurate if just historical evidence provided the model's input. But that's not the case. There's plenty of forward-looking considerations contributing to MYNZ's case of deserving a more appropriate and higher valuation. https://www.benzinga.com/pressreleases/23/02/ab31084658/mainz-biomeds-milestones-reached-in-2022-can-be-catalysts-in-1h-2023-heres-why-mynz

[cuggegrosse]

Very,very low float !!!!

[cuggegrosse]

If it ever comes !!!!!

[l2 hunter]

MYNZ excellent NEWS OUT >>>>>>>>>> Looks like big time coming. Loaded some shares for 10 X potential for 2023/24 imho...

https://www.globenewswire.com/news-release/2022/12/06/2567955/0/en/Mainz-Biomed-Announces-IRB-Approval-and-Initiation-of-US-Pivotal-FDA-Clinical-Study.html


Ticker Buzz Cloud
24 Hours
12 Hours
6 Hours
3 Hours
1 Hour
AABB
AGYP
AITX
AMC
ANY
APCX
APSI
ARIS
AVXL
BIEL
BIG
BLUE
BOMO
BRLL
CAN
CGRA
CLNV
CNNA
COMS
COSM
CPHI
DBGI
DBMM
DRGV
ENZC
ERBB
FOR
GDVM
GOLD
GRPS
GVSI
ICNM
IGEX
IN
INKW
KBLB
KRTL
LLLI
MASN
MJLB
MRNA
MRNJ
MULN
NBLD
NWBO
PLAN
PVSP
REAL
SBEV
SNPW
SNTX
TMNA
TOPS
TPRFF
TSLA
UPIN
WNFT
WSRC

[esi23]

FDA approval in USA will blow this up to 30-40. Market cap 140M

Outstanding 14 M
25% insider owned.

Long term winner

[BlazingStocks]

“The Company is financially well positioned to maintain momentum as ColoAlert continues to gain impressive commercial traction across Europe and select international territories, and as we ramp up to launch its U.S. pivotal clinical trial by the end of the year.”
- Guido Baechler, Chief Executive Officer of Mainz Biomed, $MYNZ

[BlazingStocks]

$MYNZ trading at the high of the day.

ColoAlert - The Company’s Flagship Product (ColoAlert) Could Become An Inexpensive Alternative In A $3.7 Billion Market? $MYNZ
https://investorbrandmedia.com/mynz-stock-alert/

[BlazingStocks]

Yes, $MYNZ had an amazing day yesterday... a continuation would be awesome.

[pumpnass]

Yesterday was a great day, let’s see if we can hold that trend today!!

[BlazingStocks]

$MYNZ - Mainz Biomed Strengthens Board of Directors...
*Dr. Dreismann, Former Roche Molecular Diagnostics CEO
*Over 35 years of experience in the life sciences and health care industries
*Mr. Tibbitts, a Highly-accomplished Life-Sciences Executive
*Certified Public Accountant with over 30 years of professional experience as a senior financial executive
*Together provide Extensive Experience in Diagnostics and Financial Strategy
https://finance.yahoo.com/news/mainz-biomed-strengthens-board-directors-110000523.html

[BlazingStocks]

Don't forget about this...$MYNZ - Another Value-Creating Asset, PancAlert...
*Advancing a second portfolio asset
*An early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR)
*Multiplex detection of molecular-genetic biomarkers in stool samples.
*Accurate real-time results
*Can be a first and best-in-class screening for pancreatic cancer
https://www.marketwatch.com/press-release/mainz-biomed-targets-multi-billion-dollar-sales-opportunities-with-best-in-class-cancer-screening-diagnostics-mynz-2022-09-26

[BlazingStocks]

$MYNZ coming up on 2x its 10-day average volume as we head into Power Hour... let's rock!

[budfoxfun]

Bids increasing, heating up here!

$MYNZ

[budfoxfun]

$MYNZ $25.8 million (gross) in new capital, having less than $1 million in long-term debt, and generating revenues from an early cancer detection diagnostics portfolio.

[BlazingStocks]

Should see $8 in power Hour again... $MYNZ

[BlazingStocks]

$MYNZ breakout! $8.01 hit and it's consolidating around $7.50... Power Hour should be interesting.

[budfoxfun]

7.65 not much on the ask now, $8's coming!

$MYNZ

[budfoxfun]

$MYNZ 7.65 up now, something brewing here!

[BlazingStocks]

WOWZA, really nice volume as $MYNZ now trading nearly 60% over its 10-day average volume with about 3 hours still left in the day... UP almost 2%.

[pumpnass]

Definitely picking up now

[BlazingStocks]

$MYNZ now trading nearly 10% over its 10-day average volume in lunchtime... Still holding steady.

[budfoxfun]

$MYNZ hot sector here:

[BlazingStocks]

Nice premarket volume and it's continuing into the open...might break its 10-day average volume within the first hour.

[BlazingStocks]

Wow, great News this morning! $MYNZ trading nearly 70% of its 10-day average volume within the first 30 minutes...and holding steady near yesterday's close.

[budfoxfun]

Looks ready for new highs on the week, ask is super thin now!

$MYNZ

[pumpnass]

Nice pre market volume

[budfoxfun]

“As we continue to build strength throughout our organization, we are honored to nominate Heiner and Gregory to our Board of Directors, two notable leaders in key areas of the diagnostics field,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The rich experience they would bring to our board, in both strategic development and financial stewardship, will be of significant value as we prepare for our imminent and pivotal US clinical trial for ColoAlert and continue to advance the development and commercialization of our portfolio of next-generation early-cancer detection products.”

$MYNZ

[budfoxfun]

$MYNZ Mid-year cash balance of $26 Million

[pumpnass]

That’s what I like to see!!

[budfoxfun]

$MYNZ News Out! Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts https://finance.yahoo.com/news/mainz-biomed-strengthens-board-directors-110000523.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

[BlazingStocks]

Let's see if we can get one more push to close green. $MYNZ

Biotech Stocks could be recession proof as bond market plunges (MYNZ, RVNC, AXSM, ABBV)
https://www.marketwatch.com/press-release/biotech-stocks-could-be-recession-proof-as-bond-market-plunges-mynz-rvnc-axsm-abbv-2022-09-26?mod=mw_quote_news_seemore

[BlazingStocks]

Agreed... The saying goes "Buy when there's blood in the streets." $MYNZ is working towards FDA approval.

Received supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trial set to commence in Q4 2022.